Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00479934 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
NotableStudy completion date changed from estimate of Dec 2009 to Dec 2010Trial status: Recruiting to Completed · Enrollment target: estimated 34 to confirmed 28 · Primary completion date changed from estimate of Dec 2009 to Jun 2010 · 1 morev5Show all 5 changesShow less
Trial status: Recruiting to Completed
Enrollment target: estimated 34 to confirmed 28
Primary completion date changed from estimate of Dec 2009 to Jun 2010
Site details revised at 12 of 12 sites
MinorRe-verified, no change to tracked fieldsv4
MinorStudy sites: 7 to 12Secondary endpoints revised (5) · Study arms: 0 to 2v3Show all 3 changesShow less
NotableTrial status: Not Yet Recruiting to RecruitingStart date: Jul 2007 to Dec 2007 · Primary completion date: Dec 2009 · Completion date: Aug 2009 to Dec 2009 · 1 morev2Show all 5 changesShow less
Start date: Jul 2007 to Dec 2007
Primary completion date: Dec 2009
Completion date: Aug 2009 to Dec 2009
Site details revised at 7 of 7 sites
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
In vitro studies have shown that imatinib 1mM inhibits strongly the growth of cutaneous fibroblasts. The hypothesis is that imatinib inhibits PDGFR which is known to be a potential target for the molecule, as recently also proposed after the discovery of autoantibodies activating the PDGF receptors. Recent data indicate that TGFb is also a potential target of imatinib. Cutaneous scleroderma is characterized by progressive cutaneous fibrosis caused by hyperactive dermal fibroblasts. Since no established treatment for skin sclerosis in scleroderma is currently available. This study will test the safety and efficacy of imatinib in the treatment of patients with scleroderma and severe cutaneous involvement.